Michael P. Gemstone, M.D http://vardenafiluk.com ., Richard S. Legro, M.D., Christos Coutifaris, M.D., Ph.D, Ruben Alvero, M.D., Randal D. Robinson, M.D., Peter Casson, M.D., Gregory M. Christman, M.D., Joel Ager, Ph.D., Hao Huang, M.D., M.P.H., Karl R. Hansen, M.D., Ph.D., Valerie Baker, M.D., Rebecca Usadi, M.D., Aimee Seungdamrong, M.D., G. Wright Bates, M.D., R. Mitchell Rosen, M.D., Daniel Haisenleder, Ph.D., Stephen A. Krawetz, Ph.D., Kurt Barnhart, M.D., J.C. Trussell, M.D., Dana Ohl, M.D., Yufeng Jin, M.S., Nanette Santoro, M.D., Esther Eisenberg, M.D., M.P.H., and Heping Zhang, Ph.D.
Statistical Analysis The principal analysis compared the proportion of patients in each group who had the primary outcome and was performed with the use of Pearson’s chi-square test in the intention-to-monitor population, which consisted of all patients who underwent randomization and for whom the atrial-fibrillation status could be assessed . Secondary analyses assessed the proportions of sufferers with atrial fibrillation detected by way of the study monitors among sufferers who underwent any monitoring. We used Pearson’s chi-square check to evaluate the proportions of patients for whom anticoagulant or antiplatelet therapy was prescribed. There have been no interim analyses.